GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
T

Teva Pharmaceutical Industries TEVA.TA · ILA

Health Care · Tel Aviv · 🇮🇱 Israel

Compare

13,580.00

+2.11%

Close of 9 Nov 2026, in ILA

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Teva Pharmaceutical Industries annual report

Figures from our data supplier

We don't hold this company's report document. It publishes it on its own website.

Company website ↗

Five-year highlights

In USD.

FY2025FY2024FY2023FY2022FY2021
Revenue$18.68bn$16.54bn$15.85bn$14.93bn$15.88bn
Operating income$4.28bn−$303.0m$433.0m−$2.10bn$1.62bn
Net income$1.53bn−$1.64bn−$559.0m−$2.35bn$417.0m
Free cash flow$2.56bn$749.0m$842.0m$1.04bn$236.0m
Total assets$40.76bn$39.33bn$43.48bn$44.01bn$47.67bn
Shareholders' equity$7.91bn$5.37bn$7.51bn$7.90bn$10.28bn

Revenue by business

Year to 31 Dec 2024

  • Product [Member] $14.43bn · 87.2%
  • Generics Medicians Including OTC And Biosimilars [Member] $1.94bn · 11.7%
  • Distribution Service [Member] $1.58bn · 9.5%
  • Anda [Member] $1.54bn · 9.3%
  • Product and Service, Other [Member] $365.0m · 2.2%
  • Other Products [Member] $349.0m · 2.1%
  • Respiratory Product [Member] $244.0m · 1.5%
  • License [Member] $173.0m · 1.0%
  • BENDEKA and TREANDA [Member] $168.0m · 1.0%
  • UZEDY [Member] $117.0m · 0.7%

Revenue by region

Year to 31 Dec 2024

  • UNITED STATES $8.03bn · 48.6%
  • Europe [Member] $5.10bn · 30.8%

Sources and methodology

Data on this tab
SEC EDGAR and our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.